Cytokinetics' cardiomyopathy drug cleared for NHS use
Cytokinetics said the UK MHRA and NICE cleared its cardiomyopathy drug Myqorzo (aficamten) for NHS use as an add-on to standard therapy in adults with NYHA class II-III obstructive hypertrophic cardiomyopathy. NICE required cost parity with Bristol Myers Squibb’s Camzyos. Myqorzo made about $5m in Q1 sales; Camzyos $314m.
How this was made
The 30-second read
Why it matters
Concurrent MHRA and NICE decisions clear NHS use as an add-on to standard therapy for NYHA class II-III obstructive HCM, positioning Myqorzo as the first rival to Bristol Myers Squibb’s Camzyos in the UK.
Market read
This is a UK commercialization catalyst for aficamten, with reimbursement clearance and a competitive read-across versus Camzyos that can affect expectations for UK patient access and monitoring economics.
What to watch
The article cites “expected later this year” availability but does not quantify NHS launch date, prescribing uptake, or patient eligibility constraints, which can limit near-term revenue impact.
Background
Cytokinetics’ aficamten (Myqorzo) is a cardiac myosin inhibitor for obstructive hypertrophic cardiomyopathy; the UK process requires both MHRA approval and NICE reimbursement recommendation.
Ticker impact
MHRA and NICE cleared Cytokinetics’ aficamten (Myqorzo) for NHS use in obstructive HCM, enabling add-on treatment for NYHA II-III adults.
Near-term upside bias from improved UK commercialization prospects; magnitude likely moderate unless rollout timing or uptake accelerates materially.
The article is a first report of UK MHRA plus NICE clearance and includes rollout timing (expected later this year) and comparative positioning versus Camzyos, which can affect competitive share expectations.
Market effects
Reinforces momentum for cardiac myosin inhibitors in Europe, potentially raising expectations for payer acceptance and competitive intensity in obstructive HCM.
Improves UK commercialization outlook for aficamten, which can influence UK-focused biotech sentiment and channel checks.
Adds to the global adoption narrative for aficamten following US, EU, China approvals, supporting broader investor confidence in the platform.
Counterpoint
NICE’s cost-effectiveness requirement implies pricing and monitoring economics are key; uptake may lag if real-world dosing/scan burden differs from HTA assumptions.
Key entities
- companyCytokinetics
Drugmaker whose aficamten (Myqorzo) received UK MHRA and NICE clearance for NHS use in obstructive HCM.
- drugMyqorzo (aficamten)
Cytokinetics’ cardiac myosin inhibitor cleared for NHS use as add-on therapy for adults with NYHA II-III obstructive HCM.
- companyBristol Myers Squibb
Maker of Camzyos, the existing NICE-approved cardiac myosin inhibitor in the same indication since 2023.
- drugCamzyos (mavacamten)
BMS’ cardiac myosin inhibitor already cleared for NHS use in similar obstructive HCM indications.
- regulatorMHRA
UK medicines regulator that cleared Myqorzo for use.
